ClinicalTrials.gg
CompletedNCT06548815Updated Aug 12, 2024

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single-dose GZR4

A Phase 1 interventional study of GZR4 and Placebo in Diabetes, sponsored by Gan and Lee Pharmaceuticals, USA. Completed at 1 site in China. Open to male participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-08-12.

Sponsored by Gan and Lee Pharmaceuticals, USA · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Registered 1 year 11 months after the study started (first participant enrolled Aug 2022, registered Aug 2024).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
43
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 14 studies in Diabetes Mellitus by Gan & Lee Pharmaceuticals — 1 open to participants now, 5 under way, 4 of them phase 3. Diabetes Mellitus · Gan & Lee Pharmaceuticals.

Enrollment
8th of 14
43 · median 79
Started
2022
the only one that year
Phase 1
7 of 14
none open now
Registered
7th of 14
by date

Among the 14 studies in Diabetes Mellitus by Gan & Lee Pharmaceuticals, this one is the 8th largest by enrollment, is the only one that started in 2022, is one of 7 in phase 1, and was the 7th registered.

Diabetes Mellitus

8,293 studies on the registry are indexed under Diabetes Mellitus; 1,072 are open to participants now.

Browse Diabetes Mellitus studies →

Open to participants now

1 of the 14 studies in Diabetes Mellitus by Gan & Lee Pharmaceuticals is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 648 Diabetes Mellitus studies recruiting now, 357 (55%) set no upper age limit and 195 (30%) stop at 75 or younger; 88 take children under 18; 182 take healthy volunteers.

This study: 18 Years to 45 Years · male · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies in Diabetes Mellitus by Gan & Lee Pharmaceuticals, or all of them as a file.
02

Study summary

This trial is conducted in China. The aim of this trial is to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of single-dose GZR4.

03

Conditions studied

  • Diabetes

Browse trials for

Keywords

  • GZR4
  • PK
04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Chinese healthy male adult subjects aged 18-45 years old
  • [BMI between 19.0-24.0 kg/m2
  • (HbA1c)≤6%

Exclusion criteria

Exclusion Criteria:

  • Abnormalities that were assessed by the investigators to be at screening included vital signs, physical examination, laboratory testing, anteroposterior and lateral chest radiography, and 12-lead
  • Known severe allergies (e.g., allergy to more than 3 allergens, allergic asthma affecting the lower respiratory tract, allergy requiring treatment) or known allergic history to the ingredients of the drug used in this study
  • Participants had donated blood ≥ 200 mL within 6 months before screening, or had donated blood components, or had a total blood loss of ≥ 200 mL due to any reason, or history of blood transfusion or use of blood products
  • (HIV) antibody, surface antigen (HBsAg), virus (HCV) antibody or treponema pallidum antibody positive
  • Participated in other clinical trials and used investigational drugs or medical devices within 3 months before screening
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
43 participants (actual)

Study arms

  • Experimental
    GZR4

    s.c, single dose

    Drug: GZR4

  • Placebo comparator
    Placebo

    s.c, single dose

    Drug: Placebo

Interventions

  • DrugGZR4

    Ascending single doses - 4 dose levels.

  • DrugPlacebo

    Ascending single doses - 4 dose levels.

06

What researchers measure

Primary outcomes

  1. Incidence of TEAE

    Time frame: Baseline to Day29

Secondary outcomes

  1. GIRmax

    Time frame: Day2-Day3

  2. Tmax,GIR

    Time frame: Day2-Day3

  3. AUCGIR

    Time frame: Day2-Day3/Day7-Day8

  4. Cmax

    Time frame: Baseline to Day29

  5. Tmax,GZR4

    Time frame: Baseline to Day29

  6. T1/2

    Time frame: Baseline to Day29

  7. AUC0-inf

    Time frame: Baseline to Day29

  8. AUC0-last

    Time frame: Baseline to Day29

07

Study locations

1 site
  • Gan & Lee Pharmaceuticals Co., Ltd
    Beijing, Beijing 100000, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2022 to primary completion in Mar 2023, 6 months.

Of 171 industry-sponsored phase 1 interventional studies under Diabetes Mellitus, half reached primary completion within 6 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 10. This study's 6 months is close to that.

Counting every sponsor, half of 247 studies reached it within 7 months; a quarter within 3 and three quarters within 17.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 5, 2024
First posted
Aug 12, 2024
StartActual
Aug 29, 2022
Primary completionActual
Mar 24, 2023
CompletionActual
Mar 24, 2023
Last update
Aug 12, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 12, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06548815
Responsible party
Sponsor
First posted
Aug 12, 2024
Start date
Aug 29, 2022
Primary completion
Mar 24, 2023
Completion
Mar 24, 2023
Last update
Aug 12, 2024

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: GZR4

Start the discussion